Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Immune Checkpoint Expression - Predicting Malignant Progression in Low-Grade Oral Dysplasia

FY 2017-18

Summary
Cancers of the mouth are a concern worldwide, and although the devastating impact of these cancers can be prevented or limited by early detection and treatment, long-term survival remains poor. Researchers aim to find ways to catch cancers at an early stage, or for lesions that are not yet cancers, to determine which ones have a greater risk of progression. Potentially cancerous lesions (PCL) that contain greater counts of abnormal cells are known to be at a greater risk of progression, but predicting the outcome of PCL that contain a low amount of cellular abnormality is challenging, as many of these lesions will not progress, making clinical management difficult. As more is known about how cancer interacts with the immune system, the possibility of using immune factors to predict progression arises. One cancer hallmark is evasion of the immune system, and recent research highlights a system of checkpoints as key in this process. Many studies have investigated two of these checkpoints: programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). They have found that blocking these checkpoints limit tumor growth, while over-expression is linked to poor survival. However, few studies investigate this relationship in oral PCL. To determine the predictive value of measuring PD-L1 and CTLA-4 in oral PCL with low-grade cellular abnormality, we will compare the expression of these checkpoints in lesions that progress to cancer and those that do not. Finding predictive markers could inform clinical management and improve survival, and contribute to the growing knowledge base surrounding tumor immune response and resistance.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
393428
Name
Lin Iris
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Immune Checkpoint Expression - Predicting Malignant Progression in Low-Grade Oral Dysplasia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cytotoxic T-Lymphocyte Associated Antigen 4; Epithelial Dysplasia; Immune Checkpoint Inhibitors; Lymphocytes, Immunohistochemistry; Malignant Transformation; Oral Potentially Malignant Lesions; Oral Squamous Cell Carcinoma; Programmed Death-Ligand 1; Risk Prediction
Abstract
Cancers of the mouth are a concern worldwide, and although the devastating impact of these cancers can be prevented or limited by early detection and treatment, long-term survival remains poor. Researchers aim to find ways to catch cancers at an early stage, or for lesions that are not yet cancers, to determine which ones have a greater risk of progression. Potentially cancerous lesions (PCL) that contain greater counts of abnormal cells are known to be at a greater risk of progression, but predicting the outcome of PCL that contain a low amount of cellular abnormality is challenging, as many of these lesions will not progress, making clinical management difficult. As more is known about how cancer interacts with the immune system, the possibility of using immune factors to predict progression arises. One cancer hallmark is evasion of the immune system, and recent research highlights a system of checkpoints as key in this process. Many studies have investigated two of these checkpoints: programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). They have found that blocking these checkpoints limit tumor growth, while over-expression is linked to poor survival. However, few studies investigate this relationship in oral PCL. To determine the predictive value of measuring PD-L1 and CTLA-4 in oral PCL with low-grade cellular abnormality, we will compare the expression of these checkpoints in lesions that progress to cancer and those that do not. Finding predictive markers could inform clinical management and improve survival, and contribute to the growing knowledge base surrounding tumor immune response and resistance.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Iris
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~